SRR4195659
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- UV_RESPONSE_DN+0.280
- HEDGEHOG_SIGNALING+0.270
- ANGIOGENESIS+0.140
- TGF_BETA_SIGNALING+0.140
- TNFA_SIGNALING_VIA_NFKB+0.130
- APICAL_JUNCTION+0.100
- HYPOXIA+0.050
- INFLAMMATORY_RESPONSE+0.050
- MITOTIC_SPINDLE+0.040
Top 10 suppressed
- BILE_ACID_METABOLISM-0.490
- OXIDATIVE_PHOSPHORYLATION-0.450
- PEROXISOME-0.450
- XENOBIOTIC_METABOLISM-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- FATTY_ACID_METABOLISM-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- ESTROGEN_RESPONSE_LATE-0.340
- ADIPOGENESIS-0.330
- MYC_TARGETS_V2-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.861 |
| 2 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.855 |
| 3 | 95d76fd3-540d-4c50-9ea9-b50fe2c37639 | — | — | 0.831 |
| 4 | AUR-AER4-TTP1-A-1-0-R-A741-41 | — | D | 0.829 |
| 5 | TCGA-A7-A26I-01B-06R-A22O-07 | — | D | 0.829 |
| 6 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.827 |
| 7 | d422cd50-9c99-49bb-8a83-988af190126e | — | — | 0.819 |
| 8 | 023160e4-1d9a-499c-9bfa-1b3aacf284f2 | — | — | 0.817 |
| 9 | ERR2278848 | — | — | 0.816 |
| 10 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.050 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |